Atossa Therapeutics said the FDA gave an orphan drug designation to its drug Z-Endoxifen to treat Duchenne muscular dystrophy. Shares gained 16% to 71 cents in after-hours trading Friday.
Atlassian was the worst-performing stock of the week, falling 19.03%. The stock ended the week at $118.55, trading at a 44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback